Zimbabwe has declined a major American healthcare agreement valued at $367m (£272m) over five years due to the United States' insistence on sensitive information.
This move became public following a official document dated December was disclosed, which showed President Emmerson Mnangagwa felt the arrangement was "lopsided".
A government spokesperson later clarified that the United States was requesting biological samples for scientific study and commercial gain while was unwilling to guarantee the benefits from future vaccines.
"We must now begin the challenging and unfortunate process of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had donated over $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged further dialogue to reach a deal acceptable to all parties so the nation's critical HIV programme can proceed.
Wider Implications
This development follows a comparable case in neighbouring Kenya, where a high court blocked a related deal with the US after concerns were filed about the security of citizens' health data.
After resuming the presidency last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral agreements to enhance openness and responsibility.
As per statements, 16 nations in Africa have to date agreed to similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration could have provided immense advantages for the people of Zimbabwe, particularly the 1.2 million currently on HIV treatment via US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to share its biological resources and data indefinitely, without any corresponding assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Put simply, our country would provide the basic resources for medical research without any assurance that the resulting innovations would be available to our citizens if a new pandemic arise."
Sovereignty and International Frameworks
Mangwana further noted that the American exit from the global health body and its push of one-on-one deals were upending systems already established via the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme designed to deal with future pandemics.
"This framework is intended to ensure that when a country contributes its samples, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome further discussions with our US partners on how future collaboration might be arranged in a manner that honours the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body stated it recognised the government's concerns, but suggested that talks need to persist since much of the country's HIV programmes depended on external financing.
"If specific concerns arise, such as those relating to data governance or agreement terms, these can often be resolved via technical clarification and negotiated safeguards," it added.
The situation underscores the ongoing tensions between receiving crucial foreign assistance and protecting local interests in an ever more interconnected world.